NCT06109714

Early Biomarker Kidney Injury Assessment After Acumen Directed Fluid Management in Cardiac Surgery

• Status: Not Yet Recruiting
• Phase: N/A
• Study type: Interventional
• Enrollment: 100 (estimated)
• Sponsor: University of Maryland, Baltimore · Academic / Other
• Sex: All
• Age: 18 Years – 90 Years
• Healthy volunteers: Accepted

Summary

This study is to assess the benefits of goal-directed fluid management with ACUMEN in cardiac surgical patients and its impact on cardiac surgery-induced kidney injury.

Detailed description

This study is to assess the benefits of goal-directed fluid management with ACUMEN in cardiac surgical patients undergoing a CABG, AVR, or CABG/AVR. Kidney injury biomarkers NGAL, Uromodulin, and Hepcidin-25 will be used to assess cardiac-induced kidney injury. Patients will be randomly enrolled in either standard care for fluid management or goal-directed fluid management with ACUMEN.

Conditions

• Renal Injury
• Acute Kidney Injury

Interventions

Type	Name	Description
OTHER	Goal Directed Fluid Therapy	Fluid administration and hemodynamic management guided with the assistance of Edwards Lifesciences ACUMEN monitor

Timeline

• Start date: 2026-04-01
• Primary completion: 2028-04-01
• Completion: 2029-12-31
• First posted: 2023-10-31
• Last updated: 2026-03-16